KB
REGN icon

Kimelman & Baird’s Regeneron Pharmaceuticals REGN Stock Holding History

Kimelman & Baird’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.3M Buy
27,671
+16,815
+155% +$11.4M 1.27% 27
2026
Q1 		$8.39M Buy
10,856
+10,542
+3,357% +$8.07M 0.69% 34
2025
Q4 		$242K Buy
314
+260
+481% +$177K 0.02% 109
2025
Q3 		$30.4K Hold
54
– – ﹤0.01% 216
2025
Q2 		$28.4K Hold
54
– – ﹤0.01% 224
2025
Q1 		$34.2K Hold
54
– – ﹤0.01% 217
2024
Q4 		$38.5K Hold
54
– – ﹤0.01% 210
2024
Q3 		$56.8K Hold
54
– – ﹤0.01% 178
2024
Q2 		$56.8K Buy
+54
New +$52.3K ﹤0.01% 176
2017
Q1 		– Sell
-550
Closed -$202K – 124
2016
Q4 		$202K Buy
+550
New +$209K 0.03% 113

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Kimelman & Baird's REGN Position: Q2 2026 in Review

Kimelman & Baird increased its Regeneron Pharmaceuticals (REGN) stake by 155% in Q2 2026, buying an estimated $11.4M and bringing the position to 27,671 shares worth $17.3M. The position accounts for 1.27% of the portfolio, ranked #27.

Kimelman & Baird first reported a position in REGN in Q4 2016 and has held it in 10 quarters since. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Kimelman & Baird held 27,671 shares of Regeneron Pharmaceuticals worth $17.3M as of Q2 2026.
  • Kimelman & Baird bought 16,815 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $11.4M.
  • Regeneron Pharmaceuticals made up 1.27% of Kimelman & Baird's portfolio in Q2 2026, its #27 holding.
  • Kimelman & Baird first reported a position in Regeneron Pharmaceuticals in Q4 2016 and has held it in 10 quarters since.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Kimelman & Baird's 13F filing for Q2 2026, filed 5 Aug 2026.